Multi‐national survey of transfusion experiences and preferences of patients with myelodysplastic syndrome

Transfusion dependence on red blood cells (RBCs) is common for patients with myelodysplastic syndromes (MDS) but transfusion practice and experience for outpatients with MDS are largely unknown.

[1]  B. Leber,et al.  RBC-Enhance: A Randomized Pilot Feasibility Trial of Red Cell Transfusion Thresholds in Myelodysplastic Syndromes , 2020, Blood.

[2]  E. Murphy,et al.  Early and sustained improvement in fatigue-related quality of life following red blood cell transfusion in outpatients , 2020, Quality of Life Research.

[3]  H. Kantarjian,et al.  Oral cedazuridine/decitabine: a phase 2, pharmacokinetic/pharmacodynamic, randomized, crossover study in MDS and CMML. , 2020, Blood.

[4]  E. Wood,et al.  Red cell transfusion in outpatients with myelodysplastic syndromes: a feasibility and exploratory randomised trial , 2020, British journal of haematology.

[5]  M. Cazzola,et al.  Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. , 2020, The New England journal of medicine.

[6]  A. Savic,et al.  Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes , 2019, Haematologica.

[7]  Yulia Lin,et al.  Outpatient transfusions: time to study what matters to patients , 2019, Transfusion.

[8]  S. Kleinman,et al.  Therapeutic impact of red blood cell transfusion on anemic outpatients: the RETRO study , 2019, Transfusion.

[9]  A. D’Alessandro,et al.  Red blood cell storage lesion: causes and potential clinical consequences. , 2019, Blood transfusion = Trasfusione del sangue.

[10]  A. Savic,et al.  Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study , 2018, Leukemia.

[11]  J. Zwaginga,et al.  Red blood cell transfusion support and management of secondary iron overload in patients with haematological malignancies in the Netherlands: a survey , 2018, Vox sanguinis.

[12]  E. Wood,et al.  Red cell transfusion thresholds in myelodysplastic syndromes: a clinician survey to inform future clinical trials , 2017, Internal medicine journal.

[13]  D. Zelterman,et al.  Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States , 2017, Transfusion.

[14]  M. Trivella,et al.  Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem cell support. , 2017, The Cochrane database of systematic reviews.

[15]  I. Koutsavlis.  Transfusion Thresholds, Quality of Life, and Current Approaches in Myelodysplastic Syndromes , 2016, Anemia.

[16]  E. Hellström-Lindberg,et al.  Self-perception of symptoms of anemia and fatigue before and after blood transfusions in patients with myelodysplastic syndromes. , 2015, European journal of oncology nursing : the official journal of European Oncology Nursing Society.

[17]  S. Shreay,et al.  A retrospective study to evaluate the time burden associated with outpatient red blood transfusions indicated for anemia due to concomitantly administered chemotherapy in cancer patients , 2012, Supportive Care in Cancer.

[18]  L. Hofbauer,et al.  The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes. , 2012, Leukemia research.

[19]  J. Astermark,et al.  Quality of life, physical function and MRI T2* in elderly low‐risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions , 2011, European journal of haematology.

[20]  J. Sloan,et al.  Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based survey. , 2008, Leukemia research.

[21]  P. Chisnall.  Mail and Internet Surveys: The Tailored Design Method , 2007, Journal of Advertising Research.

[22]  J. Bennett,et al.  The myelodysplastic syndromes: diagnosis and treatment. , 2006, Mayo Clinic proceedings.

[23]  Luca Malcovati,et al.  Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  M. Essink‐bot,et al.  Quality of life measurement in patients with transfusion‐dependent myelodysplastic syndromes , 2003, British journal of haematology.